EICHORPublic-registry site landscape for NCT03752099, “To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer”, a Metastatic Castration Resistant Prostate Cancer study sponsored by Veru Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03752099 (registry record) |
| Study title | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer |
| Official title | A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer |
| Sponsor | Veru Inc. |
| Condition(s) | Metastatic Castration Resistant Prostate Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 13 |
| Intervention(s) | VERU-111 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03752099.
Eichor generates a preliminary site-risk snapshot for NCT03752099 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
